FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Kim Jiny</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol Cytosorbents Corp [ CTSO ]									k all app Direc	tionship of Reportir all applicable) Director		10% O	ner
(Last) (First) (Middle) C/O CYTOSORBENTS CORPORATION					3. Date of Earliest Transaction (Month/Day/Year) 08/25/2022										Office below	er (give title v)		Other ( below)	specify
305 COLLEGE ROAD EAST						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) PRINCETON NJ 08540													X	Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City) (State) (Zip)																			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day)						Exec if an	Deeme cution I y nth/Day	Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Securi		ties cially Following	Form (D) o	vnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) (D)	or Pr	rice	Transa	ction(s) 3 and 4)			(41241 )
Common Stock 08/25/2						2022					1,000(1)	A	1 \$	S1.91	70,300(2)			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Da rity or Exercise (Month/Day/Year) if any		ion Date,	on Date, Transaction Code (Ins				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Insi 3 and 4)		tr.	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Numb of Share						

## **Explanation of Responses:**

- 1. The transaction reported on this Form 4 were open market purchases made by the reporting person pursuant to a trading plan adopted by the reporting person that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
- 2. Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of the Issuer's common stock upon vesting upon a "Change In Control" of the Issuer as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 1,000 shares of owned directly reported by the reporting person and reported on this Form 4.

/s/ Kathleen P. Bloch attorney-08/26/2022 in-fact for Jiny Kim

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.